GOUT DISEASE TREATMENT MARKET ANALYSIS

Gout Disease Treatment Market, By Drug Class (NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents, Others), By Disease Type (Acute Gout and Chronic Gout), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Route Of administration (Oral, Parenteral), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

In March 2023,ProtalixBioTherapeutics, Inc. a biopharmaceutical firm specializing in developing, manufacturing, and marketing recombinant therapeutic proteins using its ProCellExplant cell–based protein expression system, has initiated dosing of the first patient in its phase I First in Human (FIH) clinical trial for PRX-115. PRX-115 is Protalix's recombinant PEGylated uricase product candidate aimed at potentially treating severe cases of gout.
In March 2023,Selecta Biosciences, Inc,Biotechnology companyand Sobi,Pharmaceutical company announced positive results from the Phase 3 DISSOLVE I & II trials evaluating SEL-212 in adult patients with chronic refractory gout. DISSOLVE I (the "US Study") met its primary endpoint, with 56% of patients receiving monthly doses achieving a response of maintaining serum urate levels below 6 mg/dL for at least 80% of the time during month six.
In March 2022, Atom Bioscience reported favorable outcomes from a Phase 2a clinical trial for ABP-671, a treatment for chronic gout, conducted under randomized double-blind, placebo-controlled conditions.
In March 2022, the US Food and Drug Administration granted approval for Strides Pharma's 0.6 mg Colchicine tablets USP, indicated for the treatment and prevention of gout.